Evidence map›Paper›PMID 39075528›Full record

ArticleStem cell research & therapy2024

Robust bioprocess design and evaluation of commercial media for the serial expansion of human induced pluripotent stem cell aggregate cultures in vertical-wheel bioreactors.

Breanna S Borys, Tiffany Dang, Hannah Worden, Leila Larijani, Jessica M Corpuz, Brett D Abraham, Emilie J Gysel, Julia Malinovska, Roman Krawetz, Tamas Revay and 4 more

Abstract read
In one paragraph

Article in Stem cell research & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Breanna S Borys *Pharmaceutical Production Research Facility, University of Calgary, Calgary, AB, Canada.
Tiffany Dang *Pharmaceutical Production Research Facility, University of Calgary, Calgary, AB, Canada.
Hannah WordenPBS Biotech Inc, 4721 Calle Carga, Camarillo, CA, 93012, USA.
Leila LarijaniDepartment of Biomedical Engineering, University of Calgary, Calgary, AB, Canada.
Jessica M CorpuzDepartment of Biomedical Engineering, University of Calgary, Calgary, AB, Canada.
Brett D AbrahamPharmaceutical Production Research Facility, University of Calgary, Calgary, AB, Canada.
Emilie J GyselPharmaceutical Production Research Facility, University of Calgary, Calgary, AB, Canada.
Julia MalinovskaPharmaceutical Production Research Facility, University of Calgary, Calgary, AB, Canada.
Roman KrawetzDepartment of Biomedical Engineering, University of Calgary, Calgary, AB, Canada.
Tamas RevayDepartment of Medical Genetics, Alberta Health Services, Alberta Children's Hospital, Calgary, AB, Canada.
Bob ArgiropoulosDepartment of Medical Genetics, Alberta Health Services, Alberta Children's Hospital, Calgary, AB, Canada.
Derrick E RancourtDepartment of Biomedical Engineering, University of Calgary, Calgary, AB, Canada.
Michael S KallosPharmaceutical Production Research Facility, University of Calgary, Calgary, AB, Canada.
Sunghoon JungPBS Biotech Inc, 4721 Calle Carga, Camarillo, CA, 93012, USA. sjung@pbsbiotech.com.ORCID 0000-0003-3183-5249

Funding

Alberta Graduate Excellence Scholarship (AGES) Alberta Graduate Excellence Scholarship (AGES)Canadian Institutes of Health Research (CIHR) Canadian Institutes of Health Research (CIHR)Natural Sciences and Engineering Research Council (NSERC) Canada Graduate Scholarship Doctoral Natural Sciences and Engineering Research Council (NSERC) Canada Graduate Scholarship DoctoralVanier Graduate Scholarship Program Vanier Graduate Scholarship Program
6 · The paper itself

Abstract

backgroundWhile pluripotent stem cell (PSC) therapies move toward clinical and commercial applications at a rapid rate, manufacturing reproducibility and robustness are notable bottlenecks in regulatory approval. Therapeutic applications of PSCs require large cell quantities to be generated under highly robust, well-defined, and economically viable conditions. Small-scale and short-term process optimization, however, is often performed in a linear fashion that does not account for time needed to verify the bioprocess protocols and analysis methods used. Design of a reproducible and robust bioprocess should be dynamic and include a continuous effort to understand how the process will respond over time and to different stresses before transitioning into large-scale production where stresses will be amplified.

methodsThis study utilizes a baseline protocol, developed for the short-term culture of PSC aggregates in Vertical-Wheel

resultsThe robust nature of the expansion protocol was demonstrated over a six-day culture period where spherical aggregate formation and expansion were observed with high-fold expansions for all five commercial media tested. Profound differences in cell growth and quality were revealed only through long-term serial expansion and in-vessel dissociation operations. Some commercial media formulations tested demonstrated maintenance of cell growth rates, aggregate morphology, and high harvest recovery efficiencies through three bioreactor serial passages using multiple PSC lines. Exceptional bioprocess robustness was even demonstrated with sustained growth and quality maintenance over 10 serial bioreactor passages. However, some commercial media tested proved less equipped for serial passage cultures in bioreactors as cultures led to cell lysis during dissociation, reduction in growth rates, and a loss of aggregate morphology.

conclusionsThis study demonstrates the importance of systematic selection and testing of bioprocess input variables, with multiple bioprocess output variables through serial passages to create a truly reproducible and robust protocol for clinical and commercial PSC production using scalable bioreactor systems.

Indexed as

BioreactorsCell Culture TechniquesCulture MediaInduced Pluripotent Stem CellsCell DifferentiationCell LineCell ProliferationHumansCulture MediaBiomanufacturingInduced pluripotent stem cellMediaSerial passageStem cell bioprocessingVertical-wheel bioreactor

Identifiers

PMID39075528
PMCPMC11288049

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.